Vancomycin pharmacokinetics in normal and morbidly obese subjects

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Obesity Medicine

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive infections.
• Obesity significantly alters drug pharmacokinetics, necessitating dose adjustments.
• Gastric bypass surgery further impacts drug absorption and distribution.

Purpose of the Study:

• To determine vancomycin pharmacokinetics in morbidly obese patients post-gastric bypass surgery.
• To compare vancomycin dosing requirements between normal weight and morbidly obese individuals.
• To establish optimal dosing strategies for vancomycin in obese populations.

Main Methods:

• An uncontrolled study involving four normal weight and six morbidly obese subjects post-gastric bypass surgery.
• Determination of vancomycin terminal half-life, volume of distribution, and total body clearance.
• Correlation analysis between total body weight and pharmacokinetic parameters.

Main Results:

• Morbidly obese subjects exhibited shorter mean terminal half-lives (3.2 h vs. 4.8 h) and smaller volumes of distribution (0.26 L/kg vs. 0.39 L/kg) compared to normal controls.
• Strong correlations were observed between total body weight and both volume of distribution (r=0.943) and total body clearance (r=0.981).
• Similar daily doses (mg/kg/day) were required to achieve target vancomycin concentrations, but total daily doses (mg/day) were higher in the obese group.

Conclusions:

• Total body weight is a crucial factor for calculating vancomycin doses in morbidly obese patients.
• Shorter half-lives in obese patients may necessitate more frequent dosing to avoid accumulation.
• Optimized vancomycin dosing in obesity requires consideration of altered pharmacokinetic parameters and total body weight.